HOME >> BIOLOGY >> NEWS
Mayo researcher discovers target site for developing mosquito pesticides

ROCHESTER, Minn. -- A Mayo Clinic researcher has discovered a target site within malaria-carrying mosquitoes that could be used to develop pesticides that are toxic to the Anopheles gambiae mosquito and other mosquito species. It would not affect humans and other mammals. If supported by further studies, the findings could offer a safer and more effective control of mosquito-borne diseases such as malaria.

Yuan-Ping Pang, Ph.D., a chemist and expert in computer-aided molecular design at Mayo Clinic, identified two unique amino acid residues called cysteine (286) and arginine (339). These exist in three mosquito species and the German cockroach.

Dr. Pang's findings are significant because the residues could potentially be used as a target site for a pesticide that would incapacitate only insects that carry these residues, which do not exist in mammals. The findings appear in the current issue of PLoS ONE, a new, peer-reviewed, open-access journal published by the Public Library of Science.

"These findings suggest that new pesticides can be designed to target only the mosquito enzyme. Such pesticides could be used in small quantities to harm mosquitoes, but not mammals," Dr. Pang says. "We've developed a blueprint for a pesticide that could incapacitate malaria-carrying mosquitoes. We are currently making a prototype of the new pesticide."

Most pesticides today work by crippling the serine residue, which is another amino acid of the enzyme acetylcholinesterase and is located at the active site of the enzyme. This serine residue is present in both insects and mammals and therefore, any pesticide targeting this amino acid affects both insects and mammals.

Acetylcholinesterase is a vital enzyme to both insects and mammals. It breaks down the neurotransmitter acetylcholine, which is a primary neurotransmitter in the brain that is associated with memory and cognition.

Dr. Pang, director of Mayo Clinic's Computer-Aide
'"/>

Contact: Amy Reyes
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
20-Dec-2006


Page: 1 2 3

Related biology news :

1. Innovative tagging technique may help researchers better protect fish stocks
2. Penn researchers discover how key protein stops inflammation
3. ASU researchers partner with UOP to make biofuel for military jets a reality
4. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
5. Penn researchers discover pathway that eliminates genetic defects in red blood cells
6. U-M researchers find family of on switches that cause prostate cancer
7. 2007 EURYI: 20 young researchers to receive Nobel Prize-sized awards for breakthrough ideas
8. Pets could be source of multiresistant bacteria infections in humans, MU researchers investigate
9. MGH researchers confirm that bone marrow restores fertility in female mice
10. Smithsonians National Zoo researchers use electronic eggs to help save threatened species
11. U-M researchers identify gene involved in breast cancer

Post Your Comments:
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
(Date:11/21/2014)...  Earlier this year Donald Spector , Chairman ... of the most prolific inventors in the world, got ... Smartphones to third party agencies. Spector envisioned this technology ... the earliest known patents in this area. Now major ... child care, elder care and hospital applications. This technology ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: